Oculis Holding AG (OCS) Enterprise Value (2021 - 2026)
Oculis Holding AG's (OCS) quarterly Enterprise Value came in at -$283.5 million in Q1 2026, down 40.12% year-on-year from -$473.5 million in Q1 2025, and down 6.39% quarter-over-quarter from -$266.5 million in Q4 2025.
Oculis Holding AG (OCS) Enterprise Value (2021 - 2026) Analysis & Trends
Oculis Holding AG's Enterprise Value history runs 6 years deep, the most recent figure standing at -$283.5 million for Q1 2026.
- On a quarterly basis, Enterprise Value fell 40.12% year-over-year to -$283.5 million in Q1 2026; TTM through Mar 2026 was -$283.5 million, a 40.12% decrease from a year earlier, with the FY2025 full-year figure at -$256.9 million, down 129.09% from the prior year.
- Enterprise Value eased to -$283.5 million in Q1 2026 per OCS's latest filing, from -$266.5 million in the prior quarter.
- Across five years, Enterprise Value topped out at $51.1 million in Q3 2023 and bottomed at -$283.5 million in Q1 2026.
- The 5-year median for Enterprise Value is -$121.7 million (2024), against an average of -$115.5 million.
- Across the five-year window, Enterprise Value surged 186.92% in 2023 and plunged 730.86% in 2024, its largest moves.
- Year by year, Enterprise Value stood at -$20.5 million in 2022, then surged by 186.92% to $17.9 million in 2023, then sank by 730.86% to -$112.6 million in 2024, then sank by 136.64% to -$266.5 million in 2025, then decreased by 6.39% to -$283.5 million in 2026.
- Per Business Quant, the three latest OCS Enterprise Value figures stand at -$283.5 million (Q1 2026), -$266.5 million (Q4 2025), and -$181.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | -61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.83 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -1.91 Bn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | -3.01 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -283.54 Mn |
| Dec 31, 2025 | -266.52 Mn |
| Sep 30, 2025 | -181.49 Mn |
| Jun 30, 2025 | -193.62 Mn |
| Mar 31, 2025 | -202.35 Mn |
| Dec 31, 2024 | -112.63 Mn |
| Sep 30, 2024 | -121.74 Mn |
| Jun 30, 2024 | -130.40 Mn |
| Mar 31, 2024 | -91.58 Mn |
| Dec 31, 2023 | 17.85 Mn |
| Sep 30, 2023 | 51.11 Mn |
| Jun 30, 2023 | 33.53 Mn |
| Dec 31, 2022 | -20.54 Mn |
| Dec 31, 2021 | -50.19 Mn |